Jenscare, an innovative medical device company, announced its interim financial results for the first half of 2025, ending June 30, 2025. The company reported significant advancements across its product pipeline, focusing on interventional treatments for tricuspid, aortic, and mitral valve diseases. This diversified portfolio, Jenscare stated, is expected to fuel future growth.
The LuX-Valve Plus TTVR system, a key product for the company, achieved several key milestones. In China, the multicenter registration clinical trial is undergoing long-term follow-up, showing promising results. The NMPA registration application has been submitted and accepted. In Europe, the LuX-Valve Plus completed a six-month follow-up of its global multicenter clinical trial, with results presented at various cardiology conferences. The system is currently under registration review for CE Marking.
In the United States, LuX-Valve Plus is participating in the FDA‘s Total Product Life Cycle Advisory Program and has completed enrollment for its early feasibility study. The company is actively pursuing approval for a pivotal study.
Jenscare also noted the rapid commercial progress of its Ken-Valve TAVR system. Following its approval by the NMPA in the first half of 2025, the company reported smooth hospital adoption and active commercial implantations across China. The company highlighted positive feedback regarding the valve’s design, performance, and clinical efficacy. They specifically mentioned the valve’s suitability for large-annulus patients and those with challenging anatomies.
Furthermore, Jenscare‘s JensClip TMVr system has submitted its NMPA registration application and is currently under review. Encouraging efficacy and safety data from a one-year clinical follow-up were presented at a major cardiology conference. Pre-commercial implantations have also been successfully conducted overseas.
Jenscare outlined its global commercialization strategy, emphasizing differentiated product positioning, a global sales network, and a comprehensive training system. The company plans to leverage key opinion leaders and partnerships to accelerate market penetration and build brand recognition. In China, a strong regional distributor network supports the commercialization of Ken-Valve. Internationally, preparations are underway for the launch of LuX-Valve Plus.
Financially, Jenscare reported RMB 26 million (US$ 3.6 million) in total revenue, RMB 12 million (US$ 1.7 million) in gross profit, and RMB 8 million (US$ 1.1 million) in sales profit. While the adjusted non-IFRS loss was RMB 92 million (US$ 12.9 million), the company expressed confidence in its ability to transition to profitability as commercialization efforts progress. The company ended the period with substantial cash reserves. Jenscare expressed its commitment to continued clinical and commercial development, aiming to become a leading global medical device company. The company plans to further expand its product portfolio and optimize operational efficiency to achieve sustainable, rapid growth.
Related
